B. Tweedy, Ch. Browne
Tweedy, Browne Co All Funds (US)
Tweedy, Browne Co All Funds (US) JAZZ PHARMACEUTICALS PLC stake
total: 185
Tweedy, Browne Co All Funds (US) JAZZ trades
- Total transactions:
- 2
- New positions:
- 1
- Reduced:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Tweedy, Browne Co All Funds (US) holds 60,149 JAZZ PHARMACEUTICALS PLC (JAZZ) shares with a market value of roughly $14.49M accounting for 1.10% of the overall portfolio. To date, the estimated cost basis is nearly $189.05 for "buy" trades and estimated average "sell" price is $240.97. Tweedy, Browne Co All Funds (US) first purchased JAZZ in 2026 Q1, initially acquiring 60,209 shares. Since the initial investment in JAZZ PHARMACEUTICALS PLC (JAZZ), Tweedy, Browne Co All Funds (US) has made 1 more transaction.
When did Tweedy, Browne Co All Funds (US) buy JAZZ PHARMACEUTICALS PLC (JAZZ)?
Tweedy, Browne Co All Funds (US) first invested in JAZZ PHARMACEUTICALS PLC (JAZZ) in 2026 Q1 at the reported quarter-end price of $189.05 per share.
What's the cost basis of Tweedy, Browne Co All Funds (US)'s JAZZ stake?
The estimated cost basis for JAZZ PHARMACEUTICALS PLC (JAZZ) stake is around $189.05 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $189.05
- Weighted AVG sell price:
- $240.97
Tweedy, Browne Co All Funds (US)'s historical trades in JAZZ PHARMACEUTICALS PLC
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.10%
|
60,149
|
$240.97
|
$14,494,105
|
-0.10% (-60)
|
-0%
|
|
2026 Q1
|
0.90%
|
60,209
|
$189.05
|
$11,382,511
|
new
|
+0.9%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.